Sponsored by Guardian

Insider sources say Elon has spent two years building a device inside Tesla's facilities.

He's calling it "10x bigger than the largest product in history."

Good Morning Alerts is giving away 3 ticker symbols tied to the supply chain around it.

Entry guidance and a bonus 4th pick are included. No credit card, no trial.

See the 3 tickers, free →

Welcome back to Invested Early.

A pain-drug company whose board spent the spring fighting an activist's call for a sale agreed on Thursday to sell for $1.65 billion. Pacira BioSciences closed at $36.39, up 44.4%, 11 cents under Viatris' cash offer. Haemonetics added 17.5% on a plasma-device rollout, and a $254 million device maker pre-announced a quarter 45% above estimates.

The indexes went the other way: the Nasdaq fell 1.3%, the S&P 500 lost 0.5%, and the Russell 2000 finished flat.

Here's what's inside today:

🧮 What an 11-cent spread says about a $1.65 billion buyout
💊 The pain-drug maker that fought a sale in April and sold in October
📅 Every earnings report in the next 30 days, scored before it prints
📈 Top gainers (and biggest losers) from Thursday's session

This is not financial advice. Always do your own research. Past performance doesn't guarantee future results.

Viatris agreed on Thursday to pay $36.50 a share for Pacira BioSciences. The stock closed at $36.39. That 11-cent gap is the spread, and it is the market's one-number verdict on whether a deal closes.

The math. Buy at $36.39, tender at $36.50, and the gain is 0.3%. With a year-end close, that is roughly 1.3% annualized. A Treasury bill pays more. A spread that thin means the arbitrage desks consider the deal close to certain.

What widens a spread. Antitrust review, a financing condition, a contested shareholder vote, or a buyer with a shaky balance sheet. Viatris is paying from cash and short-term borrowings, and the structure is a tender offer that needs only a majority of shares and antitrust clearance. Nothing here gives the market a reason to demand a wider cushion.

What a negative spread means. A target trading above the offer is the market betting on a higher bid. Pacira closed below it.

Why this matters for small caps. Thursday's 44% went to the people who owned Pacira at $25.20 on Wednesday. After the announcement, what's left is 11 cents of upside against roughly $11 of downside if the deal breaks. The takeover edge in small caps is in owning cheap, cash-generating businesses before a buyer shows up. An 11-cent spread is what's left once a deal makes the front page.

Pacira BioSciences closed Thursday at $36.39, up 44.4%, after agreeing to a $36.50-a-share cash buyout from Viatris, an equity value of about $1.65 billion.

The news: Viatris will launch a tender offer for every Pacira share and expects to close by the end of 2026, subject to a majority tender and antitrust clearance. Both boards approved it unanimously. What Viatris gets:

Why it matters: Six months ago this company was telling shareholders not to sell. An activist fund, DOMA Perpetual, had "repeatedly called for the sale of Pacira" before the June annual meeting, and the board spent the spring campaigning against its nominees. Then a strategic buyer paid a 45% premium to Wednesday's $25.20 close, about 2.2 times revenue, in cash, on a morning nobody announced in advance. That is how most small-cap exits happen.

The honest risk: For anyone who didn't own it Wednesday, there is little left. Upside is 11 cents. The deal still needs antitrust clearance and a majority of shares tendered, and if it breaks, the stock likely heads back toward $25. A topping bid is possible in theory and unpriced in practice. Study it for where small-cap takeovers come from; the trade itself is finished.

Earnings season opens Tuesday with JPMorgan and Goldman Sachs, and the small caps follow through November. Our partners at AltIndex run an earnings calendar that adds what most calendars leave out: a read on each company going into its print. Every name reporting in the next 30 days gets an AI Score from 0 to 100, built daily from more than 10,000 signals (web traffic, hiring, social audience, insider trades), and a label of bullish, mixed or bearish.

On Thursday the page had FB Financial at 77 and bullish ahead of its October 13 report and Domino's at 35 and bearish the same day. It's a starting point for deciding which reports deserve a closer look. AltIndex is a partner; Invested Inc. may earn a commission on referrals.

See the earnings calendar →

Here's where Thursday's biggest moves landed. Two medtech catalysts and a pre-announced beat led the gainers, while a crypto treasury, a lidar maker and a spectrum play filled the losers side.

Pacira is covered above. Haemonetics jumped after CSL Plasma said it will move every one of its U.S. collection centers onto the company's devices by the end of 2027, and Profound Medical pre-announced a record quarter about 45% above estimates. Byrna and WISeSat.Space rose on a narrower loss and a confirmed October satellite launch.

On the loser side, Stablecoin Development, in last week's gainers table at $3.66, has fallen three straight sessions with no announcement. MicroVision hit a 52-week low after reaffirming guidance it was expected to raise, and NextNav fell after the FCC left its spectrum item off its October 29 agenda.

(Data: Yahoo Finance.)

Thursday brought a $1.65 billion buyout of a company that told its shareholders in April not to sell, a plasma-device rollout that moved a $5 billion stock 17%, and last week's stablecoin gainer closing 46% below where it was a week ago. The 44% went to whoever owned Pacira on Wednesday.

We'll keep showing you both sides.

We'll be back soon. Watching a name we should cover? Hit reply and tell us.

Cheers,
— Brandon & Blake of Invested Inc.